What does Danaher Corporation do?

Danaher Corporation is the most respected healthcare instrumentation compounder in public markets. It's an industrial conglomerate/holding company that acquires scientific instrumentation + diagnostics + bioprocessing businesses and applies the famous Danaher Business System (DBS) — an adaptation of the Toyota Production System / Kaizen lean methodology to improve how much they keep per sale and operations at each subsidiary. Key History: 1969: Steven and Mitchell Rales (brothers) buy a real estate trust 1984: Rebrand to Danaher 1988: Steven Rales applies DBS for the first time at Jacobs Vehicle Systems — the formula is born 2016: Spin-off Fortive (industrial test & measurement) 2019: Spin-off Envista Holdings (dental) Oct 2023: Spin-off Veralto (water quality + product identification) 2026: Danaher focused on 3 pure-play healthcare/life sciences segments 3 Segments (FY2025 revenue ~$24B): (1) Biotechnology (~33% revenue) — bioprocessing equipment + consumables for manufacturing biologic drugs: Cytiva (formerly GE Life Sciences, acquired for $21B in 2020) — single-use bioreactors, chromatography resins, filtration Pall (acquired 2015) — filtration + separation Aldevron — plasmid DNA + mRNA components (key supplier for Moderna/Pfizer-BioNTech vaccines) (2) Life Sciences (~30% revenue) — instrumentation for research + drug discovery: Beckman Coulter Life Sciences — flow cytometry, centrifuges, liquid handling SCIEX — mass spectrometry Leica Microsystems — research microscopes (NOT to be confused with Leica Camera or Leica Biosystems) IDT (Integrated DNA Technologies) — synthetic oligos, gene fragments, qPCR probes (3) Diagnostics (~37% revenue) — hospital clinical diagnostics: Beckman Coulter Diagnostics — hematology, chemistry, immunoassay analyzers (in >130k labs globally) Cepheid — GeneXpert rapid PCR (TB, COVID, MTB-RIF — gold standard) Leica Biosystems — pathology + histology (cancer tissue analysis) Radiometer — blood gas analyzers (point-of-care critical care) HQ: Washington DC (2200 Pennsylvania Ave NW). Employees: ~63,000 globally. CEO: Rainer M. Blair (since Sept 2020). Chair: Steven M. Rales (co-founder, Chair since 1984). Listing: NYSE (DHR), S&P 500 component. Q1 2026 (reported April 21, 2026): Revenue: $5.95B (+3.5% YoY) Core revenue: +0.5% total | Bio core +7% | LS flat | Dx flat Bioprocessing equipment orders: +30% YoY ← first positive uptick in ~2 years (2023 destocking is over) Adj diluted EPS: $2.06 (+9.5%) | GAAP $1.45 OCF $1.3B | FCF $1.1B FY26 Guidance RAISED: adj EPS $8.35-$8.55 (was $8.35-$8.50) Dividend (the cash they pay you): $0.40/share quarterly declared for payment April 24 and July 31, 2026 Annual $1.60/share, yield ~0.96% Continuous track record of dividend increases since spin-offs Masimo Acquisition (April 21, 2026): $180/share cash = $9.9B total Masimo = pulse oximetry, brain monitoring, hospital automation Joins Diagnostics segment post-close (H2 2026) Accretive: +$0.15-0.20 EPS yr 1, ~$0.70 EPS yr 5 Synergies: >$125M cost + >$50M revenue by yr 5 Financing: €2.98B euro senior notes + new $5B revolving credit facility

Why did Vectorial Data pick DHR?

DHR at $166.29 means buying the #1 healthcare instrumentation compounder at a forward price vs. profit of 19.67x (vs. historical multiple of 25-28x) — a ~30% discount right when the 2 big catalysts are turning. Here's why: (1) Bioprocessing turn confirmed Q1 2026 = the macro catalyst: equipment orders +30% YoY (first positive reading in ~2 years). The 2023 destocking (when biotechs/pharmas cut back buying after the COVID boom) is over. Management framing: 'beginning of a multi-year investment cycle,' brownfield first then greenfield. Cytiva + Pall + Aldevron together = ~$8B revenue Bio segment with operating how much they keep per sale >25%. If bio core accelerates from +7% Q1 to +10-12% FY27 (doable), that's incremental revenue of $400-500M with 40%+ drop-through. (2) Anchor moat — >75% of ALL FDA-approved biologic therapies use Cytiva technology: when a Humira biosimilar enters the market, a new CAR-T gets approved (Yescarta, Carvykti), a new gene therapy, a next-gen mRNA vaccine — manufacturing runs through Cytiva. It's the equivalent of 'Intel Inside' for biologics. When equipment orders turn (+30% Q1), the entire universe of approved biologics is the customer base that's restocking. (3) Masimo $9.9B acquisition = diagnostic pivot + 2027+ visibility: announced April 21, 2026, close H2 2026. Masimo Patient Monitoring (SpO2 sensors, brain function) joins Diagnostics segment. Accretive from year 1: +$0.15-0.20 EPS yr 1, ~$0.70 yr 5. DBS-driven synergies >$125M cost + >$50M revenue by year 5. It's the largest acquisition since Cytiva 2020. (4) FY26 guidance RAISED to $8.35-$8.55 adj EPS: explicit management confidence post-Q1. FX +0.5% tailwind on FY26 sales. (5) DBS (Danaher Business System) is the management moat: 40 years of applying Kaizen + lean to acquired companies. Track record of lifting operating how much they keep per sale +500-1000bps within 24-36 months post-acquisition. Masimo under DBS has a clear path: 16% op margin → 22-25% in 3 years. (6) Steven Rales still Chair (co-founder, 42 years): continuity of the compounder culture. The Rales family + Mitchell Rales retain >5% direct ownership + board seats. Skin in the game. (7) Spin-off optionality intact: Danaher historically does a spin every 5-7 years (Fortive 2016, Envista 2019, Veralto 2023). Next spin of Diagnostics or Life Sciences in 2027-2028 = additional value unlock. (8) Balance sheet flexible post-Masimo financing: new $5B revolving credit facility + €2.98B notes at competitive rates. Net debt/EBITDA post-Masimo ~2.5x, manageable, A-rated. (9) China VBP/diagnostic reimbursement headwind already priced in: -$75-100M in China Dx FY26 (high-single-digit decline). Management says 'manageable' — easier comparables starting Q3 2026. (10) Trough valuation: forward price vs. profit of 19.67x is the lowest since 2015. Historical 25-28x. Modest re-rating to 23x (consensus bio recovery accepted) = $194 (+17%). Full re-rating to 27x (premium compounder) = $228 (+37%). Plus dividend yield 0.96% + EPS growth +10-12% FY27-28 = reasonable total return >20% annually.

What are the risks of investing in DHR?

The risks are measurable: (1) Bioprocessing recovery could be a 'false dawn': +30% equipment orders in Q1 could be a one-quarter blip. If Q2 2026 reports flat or negative, the market punishes hard (-15-20%). The 2023 destocking was brutal; distinguishing a genuine rebound from a catch-up effect is tough just one quarter in. (2) Masimo execution risk $9.9B: complex integration, Masimo has a litigious culture (Apple Watch IP wars), founder Joe Kiani left in 2025 — key talent retention risk. If synergies don't materialize, that $9.9B in premium goodwill looks bad. (3) China VBP + structural reimbursement: ~10-12% of revenue comes from China. Volume-Based Procurement (VBP) has slashed diagnostic reagent pricing 40-60% since 2023. If new VBP rounds target immunoassay or molecular Dx, that's another $200-300M annual hit. (4) Trump tariffs 2026 = ~$350M gross: Danaher estimated $350M gross tariff impact for 2025; FY26 not separately quantified but remains a risk factor. Cytiva plants in Marlborough MA + Sweden + UK → cross-border friction. Partially offset via supply chain + footprint changes. (5) GLP-1 drugs could reduce protein therapeutics demand: Ozempic/Wegovy/Zepbound reduce obesity → lower cardiovascular disease → lower demand for certain biologic classes (statin-like dynamic). Second-order effect, low probability but measurable by 2028+. (6) Cytiva organic growth dependency: if the vaccine market (mRNA boom 2020-2022) doesn't hold, Cytiva consumables flatten. COVID tail demand is already zero. (7) CEO transition risk (low but real): Rainer Blair has been CEO since Sept 2020 — 5+ years. If he decides to step down or the board replaces him, the succession plan isn't clearly public. (8) US healthcare pricing pressure: IRA Medicare drug price negotiations Phase 2 expanding, lab payments under threat. Affects Beckman Dx + Cepheid pricing power. (9) Top 10 customer concentration: top pharma + biotechs (Pfizer, Merck, Lilly, J&J, AbbVie, Roche, Novartis, Regeneron, BMS, Sanofi) represent ~40% of Bio segment. If 2-3 of them rationalize procurement (post-merger, for example), that's concentrated revenue risk. (10) Gross margin slippage flagged by analysts (Simply Wall St): tension between the EPS growth narrative and gross margin decline (mix shift toward equipment vs. consumables). If Q2-Q3 shows an additional -50-100bps margin hit, expect multiple compression.

Does DHR pay dividends?

Yes. Danaher Corporation pays a dividend of about 0.96% per year.

How can I buy DHR with little money?

You can buy fractional shares of DHR starting from a few dollars with any broker that offers fractional shares. The Vectorial Data method: invest the same amount in every pick, every time.

When was this DHR analysis last updated?

The DHR analysis was last updated on Invalid Date.

Stocks/DHR

DHR — Danaher Corporation

HealthcareNorth AmericaUnited StatesBlockchain certified

$166.29

Target: $195.00 (+17.3%)

P/E Ratio

30.1

P/E Forward

19.7

Dividend

0.96%

Market Cap

$119B

EPS

$5.54

Consensus

Buy

What they do

Danaher Corporation is the most respected healthcare instrumentation compounder in public markets. It's an industrial conglomerate/holding company that acquires scientific instrumentation + diagnostics + bioprocessing businesses and applies the famous Danaher Business System (DBS) — an adaptation of the Toyota Production System / Kaizen lean methodology to improve how much they keep per sale and operations at each subsidiary.

Key History:

1969: Steven and Mitchell Rales (brothers) buy a real estate trust
1984: Rebrand to Danaher
1988: Steven Rales applies DBS for the first time at Jacobs Vehicle Systems — the formula is born
2016: Spin-off Fortive (industrial test & measurement)
2019: Spin-off Envista Holdings (dental)
Oct 2023: Spin-off Veralto (water quality + product identification)
2026: Danaher focused on 3 pure-play healthcare/life sciences segments

3 Segments (FY2025 revenue ~$24B):

Biotechnology (~33% revenue)** — bioprocessing equipment + consumables for manufacturing biologic drugs:
Cytiva (formerly GE Life Sciences, acquired for $21B in 2020) — single-use bioreactors, chromatography resins, filtration
Pall (acquired 2015) — filtration + separation
Aldevron — plasmid DNA + mRNA components (key supplier for Moderna/Pfizer-BioNTech vaccines)

Life Sciences (~30% revenue)** — instrumentation for research + drug discovery:
Beckman Coulter Life Sciences — flow cytometry, centrifuges, liquid handling
SCIEX — mass spectrometry
Leica Microsystems — research microscopes (NOT to be confused with Leica Camera or Leica Biosystems)
IDT (Integrated DNA Technologies) — synthetic oligos, gene fragments, qPCR probes

Diagnostics (~37% revenue)** — hospital clinical diagnostics:
Beckman Coulter Diagnostics — hematology, chemistry, immunoassay analyzers (in >130k labs globally)
Cepheid — GeneXpert rapid PCR (TB, COVID, MTB-RIF — gold standard)
Leica Biosystems — pathology + histology (cancer tissue analysis)
Radiometer — blood gas analyzers (point-of-care critical care)

HQ: Washington DC (2200 Pennsylvania Ave NW). Employees: ~63,000 globally. CEO: Rainer M. Blair (since Sept 2020). Chair: Steven M. Rales (co-founder, Chair since 1984). Listing: NYSE (DHR), S&P 500 component.

Q1 2026 (reported April 21, 2026):

Revenue: $5.95B (+3.5% YoY)
Core revenue: +0.5% total | Bio core +7% | LS flat | Dx flat
Bioprocessing equipment orders: +30% YoY ← first positive uptick in ~2 years (2023 destocking is over)
Adj diluted EPS: $2.06 (+9.5%) | GAAP $1.45
OCF $1.3B | FCF $1.1B
FY26 Guidance RAISED: adj EPS $8.35-$8.55 (was $8.35-$8.50)

Dividend (the cash they pay you):

$0.40/share quarterly declared for payment April 24 and July 31, 2026
Annual $1.60/share, yield ~0.96%
Continuous track record of dividend increases since spin-offs

Masimo Acquisition (April 21, 2026):

$180/share cash = $9.9B total
Masimo = pulse oximetry, brain monitoring, hospital automation
Joins Diagnostics segment post-close (H2 2026)
Accretive: +$0.15-0.20 EPS yr 1, ~$0.70 EPS yr 5
Synergies: >$125M cost + >$50M revenue by yr 5
Financing: €2.98B euro senior notes + new $5B revolving credit facility

Why we like it

DHR at $166.29 means buying the #1 healthcare instrumentation compounder at a forward price vs. profit of 19.67x (vs. historical multiple of 25-28x) — a ~30% discount right when the 2 big catalysts are turning. Here's why:

Bioprocessing turn confirmed Q1 2026 = the macro catalyst: equipment orders +30% YoY (first positive reading in ~2 years). The 2023 destocking (when biotechs/pharmas cut back buying after the COVID boom) is over. Management framing: 'beginning of a multi-year investment cycle,' brownfield first then greenfield. Cytiva + Pall + Aldevron together = ~$8B revenue Bio segment with operating how much they keep per sale >25%. If bio core accelerates from +7% Q1 to +10-12% FY27 (doable), that's incremental revenue of $400-500M with 40%+ drop-through.
Anchor moat — >75% of ALL FDA-approved biologic therapies use Cytiva technology: when a Humira biosimilar enters the market, a new CAR-T gets approved (Yescarta, Carvykti), a new gene therapy, a next-gen mRNA vaccine — manufacturing runs through Cytiva. It's the equivalent of 'Intel Inside' for biologics. When equipment orders turn (+30% Q1), the entire universe of approved biologics is the customer base that's restocking.
Masimo $9.9B acquisition = diagnostic pivot + 2027+ visibility: announced April 21, 2026, close H2 2026. Masimo Patient Monitoring (SpO2 sensors, brain function) joins Diagnostics segment. Accretive from year 1: +$0.15-0.20 EPS yr 1, ~$0.70 yr 5. DBS-driven synergies >$125M cost + >$50M revenue by year 5. It's the largest acquisition since Cytiva 2020.
FY26 guidance RAISED to $8.35-$8.55 adj EPS: explicit management confidence post-Q1. FX +0.5% tailwind on FY26 sales.
DBS (Danaher Business System) is the management moat: 40 years of applying Kaizen + lean to acquired companies. Track record of lifting operating how much they keep per sale +500-1000bps within 24-36 months post-acquisition. Masimo under DBS has a clear path: 16% op margin → 22-25% in 3 years.
Steven Rales still Chair (co-founder, 42 years): continuity of the compounder culture. The Rales family + Mitchell Rales retain >5% direct ownership + board seats. Skin in the game.
Spin-off optionality intact: Danaher historically does a spin every 5-7 years (Fortive 2016, Envista 2019, Veralto 2023). Next spin of Diagnostics or Life Sciences in 2027-2028 = additional value unlock.
Balance sheet flexible post-Masimo financing: new $5B revolving credit facility + €2.98B notes at competitive rates. Net debt/EBITDA post-Masimo ~2.5x, manageable, A-rated.
China VBP/diagnostic reimbursement headwind already priced in: -$75-100M in China Dx FY26 (high-single-digit decline). Management says 'manageable' — easier comparables starting Q3 2026. (10) Trough valuation: forward price vs. profit of 19.67x is the lowest since 2015. Historical 25-28x. Modest re-rating to 23x (consensus bio recovery accepted) = $194 (+17%). Full re-rating to 27x (premium compounder) = $228 (+37%). Plus dividend yield 0.96% + EPS growth +10-12% FY27-28 = reasonable total return >20% annually.

Key Risk

The risks are measurable:

Bioprocessing recovery could be a 'false dawn': +30% equipment orders in Q1 could be a one-quarter blip. If Q2 2026 reports flat or negative, the market punishes hard (-15-20%). The 2023 destocking was brutal; distinguishing a genuine rebound from a catch-up effect is tough just one quarter in.
Masimo execution risk $9.9B: complex integration, Masimo has a litigious culture (Apple Watch IP wars), founder Joe Kiani left in 2025 — key talent retention risk. If synergies don't materialize, that $9.9B in premium goodwill looks bad.
China VBP + structural reimbursement: ~10-12% of revenue comes from China. Volume-Based Procurement (VBP) has slashed diagnostic reagent pricing 40-60% since 2023. If new VBP rounds target immunoassay or molecular Dx, that's another $200-300M annual hit.
Trump tariffs 2026 = ~$350M gross: Danaher estimated $350M gross tariff impact for 2025; FY26 not separately quantified but remains a risk factor. Cytiva plants in Marlborough MA + Sweden + UK → cross-border friction. Partially offset via supply chain + footprint changes.
GLP-1 drugs could reduce protein therapeutics demand: Ozempic/Wegovy/Zepbound reduce obesity → lower cardiovascular disease → lower demand for certain biologic classes (statin-like dynamic). Second-order effect, low probability but measurable by 2028+.
Cytiva organic growth dependency: if the vaccine market (mRNA boom 2020-2022) doesn't hold, Cytiva consumables flatten. COVID tail demand is already zero.
CEO transition risk (low but real): Rainer Blair has been CEO since Sept 2020 — 5+ years. If he decides to step down or the board replaces him, the succession plan isn't clearly public.
US healthcare pricing pressure: IRA Medicare drug price negotiations Phase 2 expanding, lab payments under threat. Affects Beckman Dx + Cepheid pricing power.
Top 10 customer concentration: top pharma + biotechs (Pfizer, Merck, Lilly, J&J, AbbVie, Roche, Novartis, Regeneron, BMS, Sanofi) represent ~40% of Bio segment. If 2-3 of them rationalize procurement (post-merger, for example), that's concentrated revenue risk. (10) Gross margin slippage flagged by analysts (Simply Wall St): tension between the EPS growth narrative and gross margin decline (mix shift toward equipment vs. consumables). If Q2-Q3 shows an additional -50-100bps margin hit, expect multiple compression.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked DHR on 2026-05-13 at $166.29.

Last updated: Invalid Date

Dividends received by the Vectorial portfolio

What this stock has paid the model since we bought it. Your actual amount depends on when you replicated.

Ex-div date	Per share	Shares	Total to portfolio
Jun 26, 2026	$0.4000	0.3013	$0.12

Total received: $0.12

Full Research

Danaher Corporation (DHR) — Research Completo

Precio: $166.29 | P/E TTM: 30.05 | P/E Forward: 19.67 | Div Yield: 0.96% | Market Cap: $119.0B

¿Qué es Danaher?

Danaher es el compounder #1 de healthcare instrumentación del mercado público — un holding industrial que adquiere empresas de instrumentación científica + diagnósticos + bioprocessing y les aplica el famoso Danaher Business System (DBS).

Historia clave:

1969: Steven y Mitchell Rales (hermanos) compran un real estate trust
1984: rebrand a Danaher
2015: adquiere Pall Corporation por $13.8B
2020: adquiere Cytiva (ex-GE Life Sciences) por $21.4B — el deal definitorio
2023: spin-off Veralto (oct 2023)
21 abril 2026: adquiere Masimo por $9.9B cash

3 Segmentos

Biotechnology (~33% revenue)

Cytiva: single-use bioreactors, chromatography, filtration → >75% de biologics FDA-aprobados usan Cytiva
Pall: filtration + separation
Aldevron: plasmid DNA + mRNA components (Moderna/Pfizer-BioNTech proveedor)

Life Sciences (~30% revenue)

Beckman Coulter Life Sciences: flow cytometry, centrifuges
SCIEX: mass spectrometry
Leica Microsystems: research microscopes
IDT: oligos sintéticos, gene fragments

Diagnostics (~37% revenue)

Beckman Coulter Diagnostics: >130k labs globales
Cepheid: GeneXpert PCR rápido (TB, COVID, sepsis)
Leica Biosystems: pathology cáncer
Radiometer: blood gas analyzers

Q1 2026 — Reportado 21 abril 2026

Métrica	Q1 2026	YoY
Revenue	$5.95B	+3.5%
Bioprocessing equipment orders	—	+30% ← turn confirmado
Bio core revenue	—	+7%
Adj diluted EPS	$2.06	+9.5%
GAAP EPS	$1.45	—
Op cash flow	$1.3B	—
FCF	$1.1B	—

FY26 Guidance RAISED: adj EPS $8.35-$8.55 (era $8.35-$8.50)

Masimo Acquisition — 21 abril 2026

$180/sh cash = $9.9B total
Va a segmento Diagnostics
Close H2 2026 (regulatory + customary)
Accretive: +$0.15-0.20 EPS yr 1, ~$0.70 yr 5
Sinergias: >$125M costo + >$50M revenue por año 5
Financiamiento: €2.98B senior notes + $5B revolving credit nuevo

Anchor Fact

>75% de TODAS las terapias biológicas FDA-aprobadas se fabrican usando tecnología Cytiva.

Fuente: Cytiva corporate disclosure.

Implicación: el customer base = universo entero de biologics aprobados. Cuando bioprocessing orders turn (+30% Q1 2026), todo ese universo está re-stocking.

Tesis en una línea

Comprar el compounder #1 de healthcare instrumentación a P/E forward 19.67x (descuento 30% vs histórico 25-28x) justo cuando (1) bioprocessing orders turn +30% Q1 2026, (2) Masimo $9.9B agrega $3B+ revenue + sinergias DBS, (3) guidance FY26 raised — con Cytiva moat (>75% biologics FDA-aprobados) intacto.

Research fecha: 13 May 2026 | Próxima revisión: Nov 2026

Esto no es asesoría financiera.

More picks in Healthcare

See all Healthcare picks →

More picks from United States

See all picks from United States →

Researched: 5/13/2026Updated: 5/13/2026Next review: 11/13/2026

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.